🔗 Share this article

The recently developed medications for gonorrhoea in decades are being viewed as a "huge turning point" in the fight against increasingly resistant strains of the infection, according to health experts.

A Worldwide Challenge

The sexually transmitted infection are escalating worldwide, with data suggesting more than 82 million new cases each year. Particularly high rates are seen in the African continent and nations within the WHO's designated area, which spans from Mongolia and China to New Zealand. In England, cases have reached a all-time high, while rates across Europe in 2023 were significantly elevated compared to those in 2014.

“The clearance of novel therapies for gonorrhoea is an significant and necessary advancement in the reality of increasing worldwide cases, the spread of superbugs and the extremely scarce available drugs currently available.”

Public health authorities are particularly alarmed about the rise in treatment-resistant strains. The global health body has designated it as a "high-priority threat". A tracking program found that resistance to key first-line drugs like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Two New Drugs Gain Authorization

One new antibiotic, also known as a brand name, was cleared by the US FDA in mid-December for treating gonorrhoea. This STI can lead to significant complications, including the inability to conceive. Researchers hope that targeted use of this new drug will help delay the spread of drug resistance.

Another new antibiotic, created by the pharmaceutical company GSK, gained clearance in concurrent days. This drug, which is also used to treat urinary tract infections, was shown in trials to be able to combat superbug versions of the gonorrhoea bacteria.

An Innovative Partnership

This new treatment was the result of a unique collaborative effort for drug creation. The charitable organization Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company Innoviva to develop it.

“This milestone signifies a major breakthrough in the treatment of highly resistant gonorrhoea, which previously has been evolving faster than antibiotic development.”

Testing Data and Worldwide Availability

Based on results detailed in a major medical journal, the new drug eradicated more than 90% of cases of the STI. This places it at an equal footing with the existing first-line therapy, which uses a dual-drug approach. The study involved over 900 participants from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its development partnership, the non-profit has the ability to license and sell the drug in many low-income and middle-income countries.

Clinicians treating patients have expressed hope. Access to a single-dose, oral treatment of this kind is seen as a "revolutionary step" for managing the epidemic. This is viewed as vital to lessen the impact of the infection for individuals and to halt the transmission of untreatable gonorrhoea globally.